This database contains 1041 studies, archived under the term: "male"
Click here to filter this large number of results.
Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson’s disease
Witt, Karsten,
Daniels, Christine,
Krack, Paul,
Volkmann, Jens,
Pinsker, Markus O.,
Kloss, Manja,
Tronnier, Volker,
Schnitzler, Alfons,
Wojtecki, Lars,
Bötzel, Kai,
Danek, Adrian,
Hilker, Rüdiger,
Sturm, Volker,
Kupsch, Andreas,
Karner, Elfriede,
Deuschl, Günther
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) significantly improves quality of life (QoL) in Parkinson’s disease (PD). Dementia is considered as a contraindication for STN-DBS. However, no controlled study assessed the impact of STN-DBS on the QoL and motor outcome in PD patients with a borderline global cognitive impairment. We studied clinical baseline […]
A randomized feasibility study of a 12-week community-based exercise program for people with Huntington’s disease
Busse, Monica,
Quinn, Lori,
Debono, Katy,
Jones, Karen,
Collett, Johnathan,
Playle, Rebecca,
Kelly, Mark,
Simpson, Sharon,
Backx, Karianne,
Wasley, David,
Dawes, Helen,
Rosser, Anne
BACKGROUND AND PURPOSE: The beneficial role of exercise as a treatment approach in Huntington’s disease (HD) has support from both preclinical work and small-scale studies; however, there have been no controlled studies of gym-based exercise in people with HD. This phase 2 randomized trial (ISRCTN 59910670) assessed feasibility, safety, acceptability, and benefit of a structured […]
Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer’s disease
Cummings, Jeffrey,
Froelich, Lutz,
Black, Sandra E.,
Bakchine, Serge,
Bellelli, Giuseppe,
Molinuevo, José L.,
Kressig, Reto W.,
Downs, Pamela,
Caputo, Angelika,
Strohmaier, Christine
Aim: Determine whether patients with Alzheimer’s disease demonstrating functional and cognitive decline, following 24-48 weeks of open-label treatment with 9.5 mg/24 h (10 cm(2)) rivastigmine patch, benefit from a dose increase in a double-blind (DB) comparative trial of two patch doses.; Methods: Patients meeting prespecified decline criteria were randomized to receive 9.5 or 13.3 mg/24 […]
Donepezil and memantine for moderate-to-severe Alzheimer’s disease
Howard, Robert,
McShane, Rupert,
Lindesay, James,
Ritchie, Craig,
Baldwin, Ashley,
Barber, Robert,
Burns, Alistair,
Dening, Tom,
Findlay, David,
Holmes, Clive,
Hughes, Alan,
Jacoby, Robin,
Jones, Rob,
Jones, Roy,
McKeith, Ian,
Macharouthu, Ajay,
O'Brien, John,
Passmore, Peter,
Sheehan, Bart,
Juszczak, Edmund,
Katona, Cornelius,
Hills, Robert,
Knapp, Martin,
Ballard, Clive,
Brown, Richard,
Banerjee, Sube,
Onions, Caroline,
Griffin, Mary,
Adams, Jessica,
Gray, Richard,
Johnson, Tony,
Bentham, Peter,
Phillips, Patrick
Background: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer’s disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease.; Methods: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer’s […]
Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial
Hanney, Marisa,
Prasher, Vee,
Williams, Nicola,
Jones, Emma L.,
Aarsland, Dag,
Corbett, Anne,
Lawrence, Dale,
Yu, Ly-Mee,
Tyrer, Stephen,
Francis, Paul T.,
Johnson, Tony,
Bullock, Roger,
Ballard, Clive
Background: Prevalence of Alzheimer’s disease in people with Down’s syndrome is very high, and many such individuals who are older than 40 years have pathological changes characteristic of Alzheimer’s disease. Evidence to support treatment with Alzheimer’s drugs is inadequate, although memantine is beneficial in transgenic mice. We aimed to assess safety and efficacy of memantine […]
Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial
Fox, Chris,
Crugel, Monica,
Maidment, Ian,
Auestad, Bjorn Henrik,
Coulton, Simon,
Treloar, Adrian,
Ballard, Clive,
Boustani, Malaz,
Katona, Cornelius,
Livingston, Gill
Background: Agitation in Alzheimer’s disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and mortality. There are no memantine trials in clinically significant agitation but post-hoc analyses in other populations found reduced agitation. We tested the primary […]
Cognitive stimulation therapy (CST) for people with dementia–who benefits most?
Aguirre, E.,
Hoare, Z.,
Streater, A.,
Spector, A.,
Woods, B.,
Hoe, J.,
Orrell, M.
Background: The efficacy of cognitive stimulation therapy (CST) has been demonstrated, but little is known about the characteristics of people with dementia, which may predict a more positive response to CST. This study sought to investigate which factors may predict response to CST.; Methods: Two hundred and seventy-two participants with dementia took part in a […]
Memantine and brain atrophy in Alzheimer’s disease: a 1-year randomized controlled trial
Wilkinson, David,
Fox, Nick C.,
Barkhof, Frederik,
Phul, Ravinder,
Lemming, Ole,
Scheltens, Philip
The primary objective of this study was to evaluate the rate of total brain atrophy (TBA) with serial magnetic resonance imaging (MRI), using the Brain Boundary Shift Integral (BBSI), in patients with probable Alzheimer’s disease (AD) over the course of 52 weeks of treatment with memantine or placebo. This was a multi-national, randomized, double-blind, placebo-controlled, […]